Biovivium Strategies’ Post

‼️Landmark decision alert! 🗣️Casgevy, a new therapy for sickle-cell disease and β-thalassaemia, could transform the way we treat these debilitating conditions. While this is great news, the technology comes with a high price tag. Sickle-cell disease can cause severe pain, and β-thalassaemia often requires regular blood transfusions. Read more about this exciting development via the link below. #WeCareAzheimers #Alz #DementiaAwareness

Inhibitor development in hemophilia is still a mystery. There is a lot that we don’t know. One question that has come up over the years is whether the product used to treat the hemophilia patient affects inhibitor development. The answer has never been clear, but we have made progress. Read more at this link: https://lnkd.in/gs4nBnMp

Inhibitor development in hemophilia is still a mystery. There is a lot that we don’t know. One question that has come up over the years is whether the product used to treat the hemophilia patient affects inhibitor development. The answer has never been clear, but we have made progress. Read more at this link: https://lnkd.in/gs4nBnMp

💡 NEW SPOTLIGHT 💡 Inter-individual variability in drug response often leads to adverse drug reactions or low drug efficacy, posing significant challenges for patient health. In this spotlight, we explored a published study by Zhou et al (2023) investigating how CYP2C29 allele frequencies translate into functional metabolic consequences. Learn more today 👉 https://lnkd.in/eNKTSQkZ

Inhibitor development in hemophilia is still a mystery. There is a lot that we don’t know. One question that has come up over the years is whether the product used to treat the hemophilia patient affects inhibitor development. The answer has never been clear, but we have made progress. Read more at this link: https://lnkd.in/gs4nBnMp

Research and investment around #exosomes and their diverse roles in health and disease continues to grow, creating a complex and competitive #IP landscape. Read our executive summary to explore key trends and IP considerations for innovators in this area. https://ow.ly/ZmNz50QIMIM

The best way to end the week… with BENEV Exosomes! What’s not to love? - Minimized downtime - Enhanced recovery - Reduced inflammation - Increased collagen production - Boosted treatment outcomes If you’re not using BENEV Exosomes in your practice, you’re missing out! DM us today to get started! #exosomeregenerativecomplex #erc #erc+ *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.

Comorbidities may affect a participant's response to treatment, intensify side effects, or interact with experimental medications. All of these effects may cause unfavorable outcomes or change how successful a treatment is administered. Read our latest BioPharma Dive article and learn why acknowledging comorbidities in trial design is essential for successful outcomes: http://spr.ly/604393wJT #PharmaResearchServices #ClinicalTrials

If you have not yet jumped on the Exosomes train, this might be your sign! In a recent article, @realself reviewed why it is SOOOO crucial as a provider in 2024 to have solutions that reduce treatment downtime and improve outcomes. Want to learn more? Click the link in our bio! #benevexosomes #benev+exocobio #exosometechnology *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.